🧐How does the gut microbiome influence treatment response across cancer types❓
👉Comprehensive review Gastroenterology
doi.org/10.1053/j.gast…

✅ Host-oncomicrobiome-therapy interactions
✅ Therapy outcomes can be modulated by reshaping the microbiom

ESMO - Eur. Oncology OncoAlert

🔥Targeting the ERBB2 in gastroesophageal carcinoma🔥
Annals of Oncology
doi.org/10.1016/j.anno…
👉comprehensive review from signaling, clinical diagnosis, anti-ERBB2 therapies to resistance mechanisms

OncoAlert ESMO - Eur. Oncology #gastriccancer

🔥Adding SBRT to Sorafenib Improves Survival and Time to Disease Progression in Patients With Advanced #HCC 🔥
💪NRG Oncology/RTOG 1112 phs-III presented by Laura Dawson at ASTRO meeting
👉multidisciplinary tumorboard is key

EASL Education ESMO - Eur. Oncology #LiverTwitter

ascopost.com/news/october-2…

🔥The next ESMO CLINICAL PRACTICE GUIDELINE published🔥
Annals of Oncology
doi.org/10.1016/j.anno…

👉Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
😀all you need....

ESMO - Eur. Oncology OncoAlert #CRC

Great news: FDA approves STRIDE regimen for unresectable #HCC based on HIMALAYA!

•IMJUDO in combination with durvalumab for hepatocellular carcinoma
•IMFINZI in combination with tremelimumab for hepatocellular carcinoma

EASL Education ESMO - Eur. Oncology #livertwitter OncoAlert

✅Regulatory approval of pertuzumab plus trastuzumab for pre-treated HER2-positive metastatic colorectal cancer using real-world data in Japan
Oncology Advance
doi.org/10.1016/j.clcc…
👉We need RWD to get (faster) approvals for 🎯therapies in rare cancers❗️

ESMO - Eur. Oncology OncoAlert

🧐Feasibility of NGS from cytological samples/ EUS-FNA in #PDAC
CGH
doi.org/10.1016/j.cgh.…
✅88% concordance btw surgical and cytological samples
🎯alterations in 15-20% of cases
👉reassuring, but can be challenging...

ESMO - Eur. Oncology OncoAlert #PrecisionMedicine

🔥Excellent meta-analysis on the value of PD-L1 for #immunotherapy in #gastriccancer 🔥
JAMA Oncology
doi.org/10.1001/jamaon…
✅17 phs-3: 11677pts -> PDL1 & MSI strongest predictor of OS:
👉SCC: TPS
👉AC: MSI & CPS
👉PDL1 should be implemented to select pts for ICI

ESMO - Eur. Oncology OncoAlert

🔥Important observation on anti-drug antibodies to atezolizumab in #HCC 🔥
JAMA Oncology
doi.org/10.1001/jamaon…
✅ 17% of pts with high level ADAs
👉atezo concentration⬇️, CD8-positive
T-cell proliferation⬇️
👉negative predictive for ORR, PFS & OS

ESMO - Eur. Oncology EASL Education #livertwitter

🔥Age-associated differences in the cancer🔥
Trends in Cancer
doi.org/10.1016/j.trec…
👉Interesting summary on major differences in the genomic, transcriptomic, epigenetic, and immunological landscapes between cancer in younger and older patients

ESMO - Eur. Oncology OncoAlert

🔥Hot off the press: Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up🔥
Annals of Oncology
doi.org/10.1016/j.anno…
👉as always, very detailed and extremely helpful for daily clinical work....

ESMO - Eur. Oncology OncoAlert

🔥Targeting FGFR2b in gastric & gastro-oesophageal junction adenocarcinoma🔥
The Lancet Oncology
doi.org/10.1016/S1470-…
✅FIGHT: FOLFOX6 + plc. vs bemarituzumab
👉mPFS: 9.5 vs 7.5 mo, n.s.
👉mOS: 19.2 vs 13.5 mo
⛔️eye tox & stomatitis
✅FORTITUDE-101/102 ongoing

ESMO - Eur. Oncology OncoAlert

🔥Comprehensive characterization of KRAS WT #pancreaticcancer 🔥
Nature Communications
doi.org/10.1038/s41467…
👉high freq. of fusions (6-67%)>BRAF, NRG1, NTRK, FGFR2
👉R5A2, PROX1 & chr1q amplification > druggable 🎯?
👉transcriptome similar to #CCA
🧐KRAS testing in #PDAC key

ESMO - Eur. Oncology

💞Good news for all ☕️drinkers😃
European Society of Cardiology Journals
doi.org/10.1093/eurjpc…
👉Caffeinated and decaffeinated coffee (3-5 cups/d) reduces incident CVD and all-cause and cardiovascular mortality risks
😇what more could you ask for? no details on espresso...

🔥Biomarker analysis from phs-II study of nivolumab in
biliary tract cancer🔥
doi.org/10.1016/j.ejca…

👉potential candidates: tumor PD-L1, CD8 T cell infiltration and high ratio of CD8/reg. T cells, 6-gene signature
❗️promising, but we need more

ESMO - Eur. Oncology OncoAlert ENSCCA_2020

🔥FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? 🔥
ejcancer.com/article/S0959-…

✅4 intersting cases responding to FGFRi
👉all KRAS WT with comparable long survival
🧐non-typical fusion partners
🎯Early NGS in KRAS WT #PDAC ❗️
ESMO - Eur. Oncology OncoAlert

🔥Interesting study on synchronous & metachronous liver mets from #CRC over the last decades🔥
JAMA Network Open
doi.org/7710.1001/jama…
👉no change for synchronous mets
👉metachronous: incidence 2-fold ⬇️, survival ⬆️

🧐Useful for patient stratification

ESMO - Eur. Oncology OncoAlert

🔥Anti-tumor efficacy of a potent and selective
non-covalent KRASG12D inhibitor🔥
Nature Medicine
doi.org/10.1038/s41591…

👉Highly effective in human xenograft models, specifically in #PDAC > context specific
💪co-targeting of EGFR, PI3Kα or SHP2 promising🎯

ESMO - Eur. Oncology OncoAlert

🔥RNF43 mutations predict response to BRAFi/EGFRi in BRAFV600E #CRC 🔥
Nature Medicine
doi.org/10.1038/s41591……

👉🎯GA do not guarantee response -> understanding resistance is key
👉mRNF43 in 29% in CRC BRAF-V600E
👉cross-talk btw MAPK & WNT > Co-mutations matter❗️

ESMO - Eur. Oncology